A Safety and Tolerability Study of Jaktinib

• Status: Not yet recruiting
• Trial end date: 2023-11-30
• Target enrollment: 0
• Participant gender: All

Summary

This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Criteria

Inclusion Criteria:

• Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia).

• Relapsed/refractory to a marketed (FDA approved) JAK inhibitor.

• At least 18 years of age.

• ECOG PS 0, 1, or 2.

• Expected life expectancy is greater than 24 weeks.

Exclusion Criteria:

• Any chemotherapy, immunomodulatory therapy, immunosuppressive therapy, corticosteroids, or growth factor treatment within 14 days prior to initiation of study drug.

• Major surgery or radiation therapy within 28 days prior to initiation of study drug.

• With suspected allergies to jaktinib or its excipient.

• Another clinical trial of a new drug or medical instrument within 3 months before screening.

• Females who are pregnant, currently breastfeeding, planning to become pregnant.

• Unable to adopt effective contraceptive methods during the study.